243 related articles for article (PubMed ID: 24323474)
1. Reversible cysteine protease inhibitors show promise for a Chagas disease cure.
Ndao M; Beaulieu C; Black WC; Isabel E; Vasquez-Camargo F; Nath-Chowdhury M; Massé F; Mellon C; Methot N; Nicoll-Griffith DA
Antimicrob Agents Chemother; 2014; 58(2):1167-78. PubMed ID: 24323474
[TBL] [Abstract][Full Text] [Related]
2. Promising Efficacy of Benznidazole Nanoparticles in Acute Trypanosoma cruzi Murine Model: In-Vitro and In-Vivo Studies.
Scalise ML; Arrúa EC; Rial MS; Esteva MI; Salomon CJ; Fichera LE
Am J Trop Med Hyg; 2016 Aug; 95(2):388-93. PubMed ID: 27246447
[TBL] [Abstract][Full Text] [Related]
3. Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi.
Puente V; Demaria A; Frank FM; Batlle A; Lombardo ME
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006764. PubMed ID: 30240395
[TBL] [Abstract][Full Text] [Related]
4. Anti-trypanosomal activity of non-peptidic nitrile-based cysteine protease inhibitors.
Burtoloso AC; de Albuquerque S; Furber M; Gomes JC; Gonçalez C; Kenny PW; Leitão A; Montanari CA; Quilles JC; Ribeiro JF; Rocha JR
PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005343. PubMed ID: 28222138
[TBL] [Abstract][Full Text] [Related]
5. Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi.
de Oliveira Filho GB; de Oliveira Cardoso MV; Espíndola JW; Ferreira LF; de Simone CA; Ferreira RS; Coelho PL; Meira CS; Magalhaes Moreira DR; Soares MB; Lima Leite AC
Bioorg Med Chem; 2015 Dec; 23(23):7478-86. PubMed ID: 26549870
[TBL] [Abstract][Full Text] [Related]
6. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.
Doyle PS; Zhou YM; Engel JC; McKerrow JH
Antimicrob Agents Chemother; 2007 Nov; 51(11):3932-9. PubMed ID: 17698625
[TBL] [Abstract][Full Text] [Related]
7. Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.
Khare S; Liu X; Stinson M; Rivera I; Groessl T; Tuntland T; Yeh V; Wen B; Molteni V; Glynne R; Supek F
Antimicrob Agents Chemother; 2015 Oct; 59(10):6385-94. PubMed ID: 26239982
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo trypanocidal synergistic activity of N-butyl-1-(4-dimethylamino)phenyl-1,2,3,4-tetrahydro-β-carboline-3-carboxamide associated with benznidazole.
Valdez RH; Tonin LT; Ueda-Nakamura T; Silva SO; Dias Filho BP; Kaneshima EN; Yamada-Ogatta SF; Yamauchi LM; Sarragiotto MH; Nakamura CV
Antimicrob Agents Chemother; 2012 Jan; 56(1):507-12. PubMed ID: 22037851
[TBL] [Abstract][Full Text] [Related]
9. 4-Chlorophenylthioacetone-derived thiosemicarbazones as potent antitrypanosomal drug candidates: Investigations on the mode of action.
Rodney Rodrigues de Assis D; Almeida Oliveira A; Luiz Porto S; Aparecida Nonato Rabelo R; Burgarelli Lages E; Corrêa Santos V; Marques Milagre M; Perdigão Fragoso S; Martins Teixeira M; Salgado Ferreira R; Renato Machado C; Antônio Miranda Ferreira L; Lucio Speziali N; Beraldo H; Simão Machado F
Bioorg Chem; 2021 Aug; 113():105018. PubMed ID: 34098396
[TBL] [Abstract][Full Text] [Related]
10. In Vitro and In Vivo Trypanosomicidal Action of Novel Arylimidamides against Trypanosoma cruzi.
Guedes-da-Silva FH; Batista DG; Meuser MB; Demarque KC; Fulco TO; Araújo JS; Da Silva PB; Da Silva CF; Patrick DA; Bakunova SM; Bakunov SA; Tidwell RR; Oliveira GM; Britto C; Moreira OC; Soeiro MN
Antimicrob Agents Chemother; 2016 Apr; 60(4):2425-34. PubMed ID: 26856830
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, activity, and molecular modeling studies of 1,2,3-triazole derivatives from natural phenylpropanoids as new trypanocidal agents.
de Souza TB; Caldas IS; Paula FR; Rodrigues CC; Carvalho DT; Dias DF
Chem Biol Drug Des; 2020 Jan; 95(1):124-129. PubMed ID: 31569301
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the Activity of Nitroisoxazole Derivatives against
Moncada-Basualto M; Saavedra-Olavarría J; Rivero-Jerez PS; Rojas C; Maya JD; Liempi A; Zúñiga-Bustos M; Olea-Azar C; Lapier M; Pérez EG; Pozo-Martínez J
Molecules; 2024 Jun; 29(12):. PubMed ID: 38930828
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the anti-Trypanosoma cruzi activity in vitro and in vivo of silibinin and silibinin in association to benznidazole.
Torchelsen FKVDS; Silva TM; Milagre MM; Silva RR; Reis LES; Branquinho RT; Silva GN; de Lana M
Parasitol Res; 2021 Apr; 120(4):1511-1517. PubMed ID: 33236174
[TBL] [Abstract][Full Text] [Related]
14. An in vitro iron superoxide dismutase inhibitor decreases the parasitemia levels of Trypanosoma cruzi in BALB/c mouse model during acute phase.
Olmo F; Urbanová K; Rosales MJ; Martín-Escolano R; Sánchez-Moreno M; Marín C
Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):110-6. PubMed ID: 26236582
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide donor trans-[RuCl([15]aneN)NO] as a possible therapeutic approach for Chagas' disease.
Guedes PM; Oliveira FS; Gutierrez FR; da Silva GK; Rodrigues GJ; Bendhack LM; Franco DW; Do Valle Matta MA; Zamboni DS; da Silva RS; Silva JS
Br J Pharmacol; 2010 May; 160(2):270-82. PubMed ID: 20128813
[TBL] [Abstract][Full Text] [Related]
16. Successful Aspects of the Coadministration of Sterol 14α-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi.
Guedes-da-Silva FH; Batista DDGJ; Da Silva CF; Pavão BP; Batista MM; Moreira OC; Souza LRQ; Britto C; Rachakonda G; Villalta F; Lepesheva GI; Soeiro MNC
ACS Infect Dis; 2019 Mar; 5(3):365-371. PubMed ID: 30625275
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of cruzipain and a cathepsin B-like target in a Trypanosoma cruzi cell line displaying resistance to synthetic inhibitors of cysteine-proteinases.
Yong V; Schmitz V; Vannier-Santos MA; de Lima AP; Lalmanach G; Juliano L; Gauthier F; Scharfstein J
Mol Biochem Parasitol; 2000 Jun; 109(1):47-59. PubMed ID: 10924756
[TBL] [Abstract][Full Text] [Related]
18. Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain.
Roush WR; Cheng J; Knapp-Reed B; Alvarez-Hernandez A; McKerrow JH; Hansell E; Engel JC
Bioorg Med Chem Lett; 2001 Oct; 11(20):2759-62. PubMed ID: 11591518
[TBL] [Abstract][Full Text] [Related]
19. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
Choe Y; Brinen LS; Price MS; Engel JC; Lange M; Grisostomi C; Weston SG; Pallai PV; Cheng H; Hardy LW; Hartsough DS; McMakin M; Tilton RF; Baldino CM; Craik CS
Bioorg Med Chem; 2005 Mar; 13(6):2141-56. PubMed ID: 15727867
[TBL] [Abstract][Full Text] [Related]
20. Novel cruzain inhibitors for the treatment of Chagas' disease.
Rogers KE; Keränen H; Durrant JD; Ratnam J; Doak A; Arkin MR; McCammon JA
Chem Biol Drug Des; 2012 Sep; 80(3):398-405. PubMed ID: 22613098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
